

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Sex differences in survival of patients with type 2 diabetes in primary care (ZODIAC-50).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-015870
Article Type:	Research
Date Submitted by the Author:	05-Jan-2017
Complete List of Authors:	Hendriks, Steven; Isala, Diabetes centre van hateren, Kornelis; Langerhans Medical Research Group Groenier, Klaas; University Medical Center Groningen, Department of General Practice Landman, Gijs; Langerhans Medical Research Group; Gelre hospital Maas, Angela; Radboud University Medical Center Bilo, Henk; Isala, Diabetes centre; University Medical Center Groningen Kleefstra, Nanne; Langerhans Medical Research Group; University Medical Center Groningen
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	type 2 diabetes, sex differences, relative survival

SCHOLARONE™
Manuscripts

1
2
3 Sex differences in survival of patients with type 2 diabetes in primary care (ZODIAC-50).
4
5
6

7 Short title: Sex differences in survival with type 2 diabetes
8
9

10
11 S.H. Hendriks MD¹, K.J.J. van Hateren MD PhD², K.H. Groenier PhD³, G.W.D. Landman
12
13 MD PhD^{2,4}, A.H.E.M. Maas MD PhD⁵, H.J.G. Bilo MD PhD FRCP^{1,6,7}, N. Kleefstra MD
14
15 PhD^{2,6}
16
17
18
19

20 ¹ Diabetes Centre, Isala, Zwolle, the Netherlands
21

22 ² Langerhans Medical Research Group, Zwolle, the Netherlands
23

24 ³ Department of General Practice, University of Groningen and University Medical Center
25
26 Groningen, Groningen, the Netherlands
27

28 ⁴ Department of Internal Medicine, Gelre hospital, Apeldoorn, the Netherlands
29

30 ⁵ Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands
31
32

33 ⁶ Department of Internal Medicine, University of Groningen and University Medical Center
34
35 Groningen, Groningen, the Netherlands;
36

37 ⁷ Department of Internal Medicine, Isala, Zwolle, the Netherlands
38
39
40
41

42 Corresponding author:
43

44 Steven H. Hendriks
45

46 Diabetes Centre, Isala
47

48 Dr. Spanjaardweg 11, 2nd floor, 8025 BT Zwolle; the Netherlands
49

50 T: +31-384247763; F: +31-384247695
51

52 E: s.hendriks@isala.nl
53
54
55
56
57
58
59
60

Abstract

Objective: To investigate sex differences in survival of primary care treated patients with type 2 diabetes in the Netherlands.

Setting: Primary care.

Participants: A total of 1815 patients who participated in a prospective observational cohort study (ZODIAC) was included of which 56% was female. Inclusion took place in 1998, 1999 and 2001. Vital status was assessed in 2013.

Main outcome measure: Relative survival of men and women with T2DM. The relative survival rate was expressed as the ratio of observed survival of patients divided by the survival of the general population in the Netherlands with comparable age.

Results: After 14 years, 888 (49%) patients had died. The relative survival rate was 0.88 (0.81 – 0.94) for men and 0.82 (0.76 – 0.87) for women with type 2 diabetes after 14 years (p-value for difference between sexes = 0.169). In patients without a history of cardiovascular diseases the relative survival was 0.99 (0.94 – 1.05) in men and 0.92 (0.87 – 0.97) in women (p-value for difference between sexes = 0.046).

Conclusions: The survival of men and women with type 2 diabetes was 12% and 18% lower, respectively, after 14 years of follow-up compared to men and women in the general population. This corresponds to a decrease in median survival of 2.2 and 3.5 years in men and women respectively. Only for T2D patients without a history of CVD a significantly lower relative survival in women compared to men with T2D was found.

Article summary: Strengths and limitations of this study

- This study provides insight in the current situation concerning the survival of men and women with type 2 diabetes who are treated in primary care in the Netherlands.
- This study used the technique of relative survival analysis, hereby a comparison between the survival of type 2 diabetes patients and the expected survival of whole general population could be made.
- The survival rates of men and women in the general population were derived from mortality rates of the entire nation.
- The generalizability is limited to primary care.
- No data were known concerning clinical variables in the general population and therefore the results of the subgroups should be interpreted with caution.

Introduction

Mortality rates in patients with type 2 diabetes (T2D) are higher compared to the general population, which is predominantly caused by a higher occurrence of cardiovascular diseases in patients with T2D (1–3). This excess mortality rate is described to be more pronounced in women compared to men with T2D (2–5). In a recent meta-analysis, the relative risk for mortality of incident coronary heart disease was 2.8 in women and 2.0 in men compared to men and women without diabetes, respectively (2).

Current knowledge on sex differences in mortality is mostly based on older cohort studies.

Whether these results are still reflecting current practice is less clear, as the care for patients with T2D has significantly improved over the last years (6). In the Netherlands, most patients with T2D receive protocol-based treatment exclusively in primary care. The mortality in this population is low, which is probably the result of a general improvement in quality of diabetes care over the last years (7). It is less well established whether sex differences in mortality also exist in well-controlled primary care patients. Only a few studies have been recently conducted in countries with a comparable care system to the Netherlands (8–10). A study from Norway also described a more pronounced excess mortality rate in women with T2D, however this study also included secondary care treated patients (10). A retrospective study from the U.K in primary care found only a slightly higher hazard ratio for all-cause mortality in women than in men with T2D, when compared with non-diabetics (8).

The aim of the present study was to investigate the survival of prospectively followed men and women with T2D, treated in primary care, compared to men and women in the general population.

Materials and Methods

Study population and design

1
2
3 The study population consisted of patients who were included in the Zwolle Outpatient
4 Diabetes Project Integrating Available Care (ZODIAC) study. This study was initiated in
5 1998, in the Zwolle region of the Netherlands. The design and details of this study have been
6 published previously (11). In this study, general practitioners were assisted by hospital-based
7 diabetes specialist nurses in their care of patients with T2D. In the first year, 1,143 patients
8 with T2D were included in this prospective cohort study. Another 127 and 545 patients with
9 T2D entered this study in 1999 and 2001 respectively, resulting in a combined cohort of 1,815
10 patients. All patients with T2D were selected from general practices in Zwolle region of the
11 Netherlands. Patients with a very short life expectancy or insufficient cognitive capabilities
12 were excluded from participation as the care for these patients has not been delegated to
13 diabetes specialist nurses. Whether the life expectancy was long enough to be included in the
14 ZODIAC study was based on the judgement of the general practitioners.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The survival of this cohort was compared with the expected survival of men and women with the same age from the general population in the Netherlands. These expected survival rates were derived from data provided by Statistics Netherlands. This organization provides survival rates for men and women of every age in the Netherlands (12).

Data collection and measurements

Before participating in the ZODIAC study, T2D was already diagnosed in all individuals by their general practitioners based on the guidelines of the Dutch College of General Practitioners (2 times a fasting plasma glucose level ≥ 7 mmol/l or one time a non-fasting plasma glucose level ≥ 11.1 mmol/l accompanied by symptoms of hyperglycemia) (13).

Information on cardiovascular diseases, smoking and medication use was collected during the check-up of the patient by the general practitioner or practice nurse at baseline of the study.

Patients were considered to have a history of CVD if a history of angina pectoris, myocardial

1
2
3 infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting,
4
5 stroke or a transient ischemic attack was documented in the patient record of the general
6
7 practice. Data on heart failure was not collected as it was not properly documented at
8
9 baseline. Smoking was included in the analyses as a categorical variable (yes/no). Laboratory
10
11 and physical assessment data were collected at baseline during the annual check-up of the
12
13 patients by their general practitioner and practice nurse and included non-fasting lipid profile,
14
15 glycated hemoglobin (HbA1c), serum creatinine (SCr), urinary albumin-to-creatinine ratio
16
17 (ACR), blood pressure and information about neuropathy and diabetic retinopathy. ACR was
18
19 measured using immunonephelometry (Behring Nephelometer; Mannheim, Germany), and
20
21 blood pressure was measured twice with a Welch Allyn sphygmomanometer in the supine
22
23 position after at least 5 minutes of rest. Foot sensibility was tested with 5.07 Semmes-
24
25 Weinstein monofilaments. Neuropathy was defined as two or more errors in a test of three, at
26
27 least at one foot. Diabetic retinopathy (DRP) was investigated with a retinal camera and the
28
29 fundus photos were judged by an ophthalmologist. Microalbuminuria was defined as an
30
31 albumin-to-creatinine ratio between 3.5 and 35 mg/mmol for women and between 2.5 and 25
32
33 mg/mmol for men. Macroalbuminuria was defined as an albumin-to-creatinine ratio > 35
34
35 mg/mmol for women and > 25 mg/mmol for men. The same methods were used in each
36
37 baseline year to measure the laboratory and physical assessment data.
38
39
40
41
42
43
44

45 *Clinical endpoints*

46
47 The primary end-point was the relative survival rate of men and women with T2D compared
48
49 with the general population in the Netherlands. Secondary end-points were the relative
50
51 survival rates of patients with T2D in different subgroups, and the median survival of men
52
53 and women. Subgroups for the relative survival analyses were defined for: age (<60, 60-75
54
55 and >75 years), Body Mass Index (BMI) (<25, 25-30 and >30 kg/m²), smoking, history of
56
57
58
59
60

1
2
3 CVD, albuminuria (normo-, micro- and macroalbuminuria), microvascular complications
4
5 (defined as the presence of albuminuria, neuropathy or DRP) and for patients with a low CVD
6
7 risk (defined as non-smoking patients without a history of CVD and microvascular
8
9 complications). In 2013, vital status and cause of death of T2D patients were retrieved from
10
11 records maintained by the hospital and the general practitioners or from the nationwide
12
13 Municipal Personal Records Database. Causes of death were coded according to the
14
15 International Classification of Diseases, 9th revision (ICD-9). Cardiovascular death was
16
17 defined as death in which the principal cause of death was cardiovascular in nature, using
18
19 ICD-9 codes 390-459.
20
21
22
23
24

25 *Statistical analyses*

26
27 Statistical analyses were performed using SPSS version 20.0 for Windows (SPSS Inc.,
28
29 Chicago, Illinois, USA) and Stata 14 (StataCorp, College Station, Texas, USA). Baseline
30
31 results were expressed as mean with standard deviation (SD) or median with interquartile
32
33 range [IQR] for normally distributed and non-normally distributed data, respectively.
34
35 Differences were considered to be significant at a p-value of <0.05 . Survival was calculated
36
37 using relative survival analysis (14). The relative survival rate was calculated by measuring
38
39 the ratio of survival of patients observed in our ZODIAC cohort in comparison to the survival
40
41 of men and women with corresponding age in the same baseline year in the general
42
43 population in the Netherlands. First, interval-specific and cumulative survival rates were
44
45 measured for both the study population and the general population, using the Hakulinen
46
47 method (15). The interval-specific observed survival rate for each follow-up year of the study
48
49 population was calculated based on the number of patients at risk, the number of deaths and
50
51 the number of patients lost to follow-up in each year. The interval-specific expected survival
52
53 rate for the general population was calculated using yearly-specific survival data of the
54
55
56
57
58
59
60

1
2
3 general population (12). Consequently, the cumulative survival rate was measured for both
4
5 the study group and the general population. Finally, the relative cumulative survival rate was
6
7 calculated. The relative cumulative survival rate for the total study population is described for
8
9 each of the 14 follow-up years for men and women separately. To investigate whether the
10
11 relative survival was significant different between sexes, the p-value was calculated at 14
12
13 years of follow-up. For the subgroup analyses, the relative cumulative survival rate is only
14
15 described after 10 years of follow-up. Cumulative survival rates after 10 years are described
16
17 due to the fact that 14 years survival data were only available for patients who were included
18
19 in 1998. The relative cumulative survival rates after 10 years are therefore more reliable. P-
20
21 values for the differences between sexes were calculated at 10 years of follow-up for the
22
23 subgroup analyses. An estimation of the median survival of the study population was
24
25 calculated using linear interpolation. For the general population, linear extrapolation with the
26
27 average difference between the cumulative survivals of the general population was conducted
28
29 first, before using linear interpolation to estimate the median survival.
30
31
32
33
34
35

36 **Results**

37
38 Baseline results of the study population are described in Table 1. Fifty-six percent of the
39
40 patients were female. Mean age was 65.0 (11.8) years in men and 68.6 (11.6) years in women.
41
42 The median diabetes duration was 4.0 [1.8-9.0] and 5.0 [2.0-10.0] years in men and women,
43
44 respectively. Men smoked more frequently and had also more often albuminuria and a
45
46 previous history of CVD compared to women. Women had a higher systolic blood pressure, a
47
48 higher BMI, and more often diabetic retinopathy than men. Men were more often on diet
49
50 treatment only while women were more often on insulin. Lipid lowering drugs and
51
52 antiplatelet drugs were more often used in men.
53
54
55
56
57
58
59
60

Relative survival analyses

The incidence rate for all-cause mortality was 7.4 (6.7 – 8.2) and 7.2 (6.5 – 7.8) per 100 person years in men and women with T2D, respectively. The incidence rate for CVD mortality was 3.1 (2.7 - 3.6) and 3.0 (2.6 - 3.4) per 100 person years in men and women with T2D, respectively. The comparison between the survival of the patients with T2D and the general population is presented in Table 2 and Fig. 1 for men and women separately. After 14 years, the relative survival rate was 0.88 (95%CI: 0.81 - 0.94) for men and 0.82 (95%CI: 0.76 – 0.87) for women with T2D (p-value for difference between sexes = 0.169). The estimated median survival of men (mean age: 65.0) and women (mean age: 68.8) in the study population was 13.8 and 13.0 years, respectively. In the general population, the estimated median survival of men and women was 16.0 and 16.5 year respectively.

Subgroup analyses

The relative survival rate after 10 years for different subgroups is described in Table 3 and Fig. 2 for men and women separately. In the subgroup of T2D patients without microvascular complications, the relative survival rate of men and women with T2D was 1.01 (95%CI: 0.95 – 1.07) and 0.98 (95%CI: 0.93 – 1.03), respectively (p = 0.488). In patients with microvascular complications, the relative survival rate decreased to 0.82 (95%CI: 0.74 – 0.89) for men and 0.77 (95%CI: 0.71 – 0.84) for women with T2D (p = 0.395). In men and women with low CVD risk (defined as non-smoking patients without a history of CVD and microvascular complications) the relative survival rate was 1.08 (95%CI: 1.00 – 1.14) and 1.01 (0.94 – 1.07), respectively (p = 0.106). The relative survival rates of men <60 years, of men with a BMI between 25 and 30 kg/m², of men without a history of CVD, and of men without albuminuria were not significantly different from men in the general population. The relative survival rate in women in all these categories was significantly lower compared to

1
2
3 women in the general population. For patients without a history of CVD, the relative survival
4
5 was significantly lower in women with T2D compared to men ($p = 0.046$).
6
7

8 9 **Discussion**

10
11 In primary care treated T2D patients, the relative survival of men and women was 12% and
12
13 18% lower after 14 years of follow-up compared to age-matched men and women in the
14
15 general population, respectively. This translates into an overall decrease in median survival of
16
17 2.2 years in men and 3.5 years in women with T2D compared to men and women in the
18
19 general population. Although the relative survival of women with T2D seems to be lower than
20
21 in male counterparts, no significant difference between sexes was found in the total study
22
23 population. The survival rate in certain subgroups of men with T2D (young age, no
24
25 albuminuria, no history of CVD, BMI 25-30) was comparable to the survival rate of men in
26
27 the general population. In women in these subgroups the relative survival was significantly
28
29 lower compared to women without T2D. Only for T2D patients without a history of CVD a
30
31 significantly lower relative survival in women compared to men with T2D was found.
32
33
34
35
36

37
38 Many studies have described a higher excess mortality rate in women than in men with T2D
39
40 (4,5,16). In our study, a higher impact of T2D in women was only found in the subgroup of
41
42 patients without a history of CVD. In subgroups of patients < 60 year of age, without
43
44 albuminuria and with a BMI between 25-30 kg/m² the relative survival of women with T2D
45
46 was lower compared to women in the general population but not lower compared to the
47
48 relative survival of men with T2D. The comparable survival of men with T2D without a
49
50 history of CVD to men in the general population has partly been described before by Kalyani
51
52 et al. (17). In a population without ischemic heart disease, they found an increased risk for the
53
54 combined outcome of ischemic heart disease and mortality in women with diabetes compared
55
56 to women without diabetes whereas they found no differences in men.
57
58
59
60

1
2
3
4
5 The decrease in median survival which is found in our study seems to be smaller than those
6
7 seen in previous studies. Results from the Framingham Heart Study showed that men and
8
9 women with diabetes lived on average 7.5 (95CI: 5.5 to 9.5) and 8.2 (95CI: 6.1 to 10.4) years
10
11 less compared to men and women without diabetes. However, this cohort started between
12
13 1948 and 1951 when treatment options for T2D were limited. In a more recent study from
14
15 Canada, for both men and women at the age of 55 on average a 5.0 (95CI: 4.9 to 5.1) and 6.0
16
17 (95CI: 5.9 to 6.1) years lower life expectancy was estimated compared to men and women
18
19 without diabetes (18). Although patient characteristics differ between studies and various
20
21 methods were used to measure survival, it may indicate that the loss of life years due to
22
23 diabetes is decreasing in both men and women.
24
25
26
27
28

29
30 Although different theories have been described which may explain the observed sex
31
32 difference in the impact of diabetes on survival, it is still not completely understood.
33
34 Undertreatment of women with T2D is mentioned as a possible explaining factor. A lower
35
36 prescription percentage for aspirin and lipid lowering drugs was found in women compared to
37
38 men with T2D (19). However, in a recent study in primary care we did not find significant sex
39
40 differences in these prescribed medications (20). The sex difference in survival may also be
41
42 explained by a greater excess in cardiovascular risk factors between women with and without
43
44 T2D compared to their male counterparts (4,21). This greater excess in risk factors is
45
46 probably the result of a more favorable risk factor profile and a lower insulin resistance in
47
48 women without diabetes compared to men (21,22). Although the relatively higher risk for
49
50 women with T2D for fatal ischemic heart disease remained significant in various meta-
51
52 analyses after adjustment for other cardiovascular risk factors, it may still be an explanation as
53
54 only traditional risk factors were taken into account (2,4). The lower relative survival could
55
56
57
58
59
60

1
2
3 also be a result of a higher prevalence of obesity in women with T2D. In the Netherlands, the
4 prevalence of obesity is described to be 25 to 50% higher in women compared to men with
5 T2D, whereas the prevalence of overweight is 20 to 35% higher in men compared to women
6 in different age categories (20). Knowing that overweight is associated with a lower mortality
7 risk and obesity with a higher mortality risk compared to patient with a normal weight, this
8 could possibly be one of the explaining factors for the higher relative mortality rate in women
9 with T2D (23). Finally, the relative higher mortality in women with T2D may be a result of
10 underdiagnosis of ischemic heart disease in women. Women with T2D have less obstructive
11 coronary disease compared to men, with higher rates of microvascular coronary dysfunction
12 that may be more difficult to diagnose and treat (24). Also, a higher prevalence of
13 undiagnosed heart failure with preserved ejection fraction (HFpEF) is described in women
14 compared to men with T2D (25). When focusing on the common symptoms and diagnostic
15 criteria for ischemic heart disease and HFpEF, these diagnoses could be easily missed in
16 women. This may lead to undertreatment of women, resulting in a higher mortality when
17 having T2D.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Some limitations should be mentioned. According to Hakulinen, relative survival is the ratio
39 of the observed survival in a group of patients compared with the expected survival in a group
40 of individuals in the general population, who are comparable with the patients concerning all
41 possible factors affecting survival, except for the disease of interest (15). Our choice to
42 compare survival of patients with T2D to the general population can therefore be criticized.
43 However, the underlying assumption by the use of the expected survivals of the general
44 population is that the deaths directly due to T2D are a negligible proportion of all deaths in
45 the general population. Furthermore, no data were known concerning clinical variables in the
46 general population, as we did not use a specific control group but expected survival rates
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 which were derived from mortality rates of the entire nation. Therefore the results of the
4
5 subgroups should be interpreted with caution. The study population consisted only of patients
6
7 with T2D who are treated in primary care. Patients in secondary care often have worse
8
9 manifestations of T2D and more often macrovascular disease and will probably have a lower
10
11 survival. Furthermore, patients with a very short life expectancy or insufficient cognitive
12
13 capabilities were also excluded from participation. Although these limitations imply that the
14
15 generalizability of our results is limited to primary care, it is still representative for a large
16
17 part of the T2D population due to the fact that the majority (>85%) of the patients with T2D is
18
19 treated in primary care in the Netherlands (26).
20
21
22
23
24

25 In conclusion, the relative survival in men and women with T2D compared to the general
26
27 population was 12% and 18% lower. The results of this study further show that survival in
28
29 subgroups of men (i.e. younger men, no albuminuria, no history CVD, BMI between 25 and
30
31 30) is comparable to men in the general population, while the survival in women in these
32
33 subgroups is still lower compared to women in the general population. Only in women with
34
35 T2D without a history of CVD the impact of diabetes on survival is higher compared to men
36
37 with T2D.
38
39
40
41
42

43 Author Contributions: SHH, KJJH, KHG, HJGB and NK designed the study. SHH, KJJH and
44
45 GWDL acquired the data. SHH, KJJH and KHG analysed the data. SHH, KJJH, KHG,
46
47 GWDL, AHEMM, HJGB and NK interpreted the data. SHH and KJJH drafted the
48
49 manuscript. KHG, GWDL, AHEMM, HJGB and NK reviewed and edited the manuscript. All
50
51 authors read and approved the final manuscript.
52
53

54 Funding statement: This research received no specific grant from any funding agency in the
55
56 public, commercial or not-for-profit sectors.
57
58
59
60

1
2
3 Competing interests: None declared.
4

5 Ethics approval: This study was approved by the local ethical committee of Isala, Zwolle, the
6
7 Netherlands. All patients gave written informed consent.
8

9 Data sharing statement: No additional data are available.
10
11

12 13 14 **References**

- 15
16 1. Barnett KN, Ogston SA, McMurdo MET, Morris AD, Evans JMM. A 12-year follow-up
17 study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed
18 with Type 2 diabetes in Tayside, Scotland. *Diabet Med J Br Diabet Assoc.* 2010
19 Oct;27(10):1124–9.
20
- 21
22 2. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary
23 heart disease in women compared with men: a systematic review and meta-analysis of
24 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia.*
25 2014 Aug;57(8):1542–51.
26
- 27
28 3. Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality,
29 hospitalization for individuals with and without diabetes, and patients with diabetes
30 diagnosed early and late. *Diabetes Care.* 2013 Sep;36(9):2582–90.
31
- 32
33 4. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated
34 with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ.*
35 2006 Jan 14;332(7533):73–8.
36
- 37
38 5. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease
39 in women and men: a meta-analysis of prospective studies. *Diabetes Care.* 2000
40 Jul;23(7):962–8.
41
- 42
43 6. van Hateren KJJ, Drion I, Kleefstra N, Groenier KH, Houweling ST, van der Meer K, et
44 al. A prospective observational study of quality of diabetes care in a shared care setting:
45 trends and age differences (ZODIAC-19). *BMJ Open.* 2012;2(4).
46
- 47
48 7. Lutgers HL, Gerrits EG, Sluiter WJ, Ubink-Veltmaat LJ, Landman GWD, Links TP, et
49 al. Life expectancy in a large cohort of type 2 diabetes patients treated in primary care
50 (ZODIAC-10). *PloS One.* 2009;4(8):e6817.
51
- 52
53 8. Liang H, Vallarino C, Joseph G, Manne S, Perez A, Zhang S. Increased risk of
54 subsequent myocardial infarction in patients with type 2 diabetes: a retrospective cohort
55 study using the U.K. General Practice Research Database. *Diabetes Care.*
56 2014;37(5):1329–37.
57
- 58
59 9. Hyvärinen M, Tuomilehto J, Laatikainen T, Söderberg S, Eliasson M, Nilsson P, et al.
60 The impact of diabetes on coronary heart disease differs from that on ischaemic stroke
with regard to the gender. *Cardiovasc Diabetol.* 2009;8:17.

10. Madssen E, Vatten L, Nilsen TI, Midthjell K, Wiseth R, Dale AC. Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study. *Scand Cardiovasc J SCJ*. 2012 Aug;46(4):219–25.
11. Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Rischen RO, Meyboom-de Jong B. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. *Neth J Med*. 2005 Mar;63(3):103–10.
12. Data published by Statistics Netherlands. In Dutch: “Centraal Bureau voor de Statistiek”. [Internet]. Available from: <http://statline.cbs.nl/Statweb/selection/?DM=SLNL&PA=70701NED&VW=T>
13. Rutten GEHM, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K, et al. NHG-Standaard Diabetes Mellitus Type 2. Eerste herziening. *Huisarts Wet*. 1999;42(2):67–84.
14. Hockey R, Tooth L, Dobson A. Relative survival: a useful tool to assess generalisability in longitudinal studies of health in older persons. *Emerg Themes Epidemiol*. 2011;8(1):3.
15. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. *Biometrics*. 1982 Dec;38(4):933–42.
16. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. *Arch Intern Med*. 2002 Aug 12;162(15):1737–45.
17. Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. *Diabetes Care*. 2014;37(3):830–8.
18. Loukine L, Waters C, Choi BC, Ellison J. Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. *Popul Health Metr*. 2012;10(1):7.
19. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. *Diabetes Care*. 2005 Mar;28(3):514–20.
20. Hendriks SH, van Hateren KJJ, Groenier KH, Houweling ST, Maas AHEM, Kleefstra N, et al. Sex Differences in the Quality of Diabetes Care in the Netherlands (ZODIAC-45). *PloS One*. 2015;10(12):e0145907.
21. Wannamethee SG, Papacosta O, Lawlor DA, Whincup PH, Lowe GD, Ebrahim S, et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. *Diabetologia*. 2012 Jan;55(1):80–7.
22. Orchard TJ, Becker DJ, Kuller LH, Wagener DK, LaPorte RE, Drash AL. Age and sex variations in glucose tolerance and insulin responses: parallels with cardiovascular risk. *J Chronic Dis*. 1982 Feb;35(2):123–32.

- 1
2
3 23. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with
4 overweight and obesity using standard body mass index categories: a systematic review
5 and meta-analysis. *JAMA*. 2013 Jan 2;309(1):71–82.
6
7 24. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, et al. Sex
8 differences in presentation and outcome among patients with type 2 diabetes and
9 coronary artery disease treated with contemporary medical therapy with or without
10 prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty
11 Revascularization Investigation 2 Diabetes). *J Am Coll Cardiol*. 2013 Apr
12 30;61(17):1767–76.
13
14 25. Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten
15 GEHM, et al. High prevalence of previously unknown heart failure and left ventricular
16 dysfunction in patients with type 2 diabetes. *Diabetologia*. 2012 Aug;55(8):2154–62.
17
18 26. InEen. In Dutch: Transparante ketenzorg diabetes mellitus, COPD en VRM rapportage
19 zorggroepen over 2013. 2014 Jun.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables and figures

Table 1. Baseline characteristics of the study population.

	Total (n = 1815)	Men (n = 800)	Women (n = 1015)	p-value
Age (years)	67.0 (\pm 11.8)	65.0 (\pm 11.8)	68.6 (\pm 11.6)	<0.001
Diabetes duration (years)	4.0 (2.0-9.0)	4.0 (1.8-9.0)	5.0 (2.0-10.0)	0.017
History of CVD	605 (33.3)	307 (38.4)	298 (29.4)	<0.001
Smoking	342 (19.0)	206 (26.0)	136 (13.5)	<0.001
BMI (kg/m ²)	29.1 (\pm 4.8)	28.2 (\pm 4.1)	29.9 (\pm 5.2)	<0.001
SBP (mmHg)	151.5 (\pm 24.4)	147.2 (\pm 23.4)	155.0 (\pm 24.5)	<0.001
HbA1c (mmol/mol)	7.0 (6.3-8.1)	6.9 (6.2-8.1)	7.1 (6.4-8.1)	0.131
Creatinine (μ mol/L)	92.0 (82.0-104.0)	98.0 (89.0-109.0)	86.0 (77.0-97.0)	<0.001
Chol-HDL ratio	4.8 (3.9-5.9)	4.9 (4.0-6.0)	4.7 (3.8-5.8)	0.001
Retinopathy	190 (10.9)	70 (9.1)	120 (12.3)	0.030
Microalbuminuria	544 (30.8)	267 (34.0)	277 (28.3)	0.011
Macroalbuminuria	114 (6.5)	68 (8.7)	46 (4.7)	0.001
Neuropathy	477 (26.6)	212 (26.7)	265 (26.6)	0.931
Microvascular complications [#]	1012 (57.7)	466 (59.7)	546 (56.1)	0.120
Low CVD risk*	424 (23.4)	154 (19.3)	270 (26.6)	<0.001
DM treatment				
Diet	318 (17.5)	158 (19.8)	160 (15.8)	0.026
Oral only	1230 (67.8)	540 (67.6)	690 (68.0)	0.834
Insulin	262 (14.5)	99 (12.4)	163 (16.1)	0.028
ACEi/ARB	433 (27.1)	179 (25.1)	254 (28.7)	0.108
Lipid lowering drugs	278 (15.6)	139 (17.7)	139 (13.9)	0.030
Antiplatelet drugs	279 (15.6)	139 (17.6)	140 (14.0)	0.035
Death	888 (48.9)	381 (47.6)	507 (50.0)	0.325
CVD death	374 (20.6)	161 (20.1)	213 (21.0)	0.653

Values are depicted as n (%), mean (\pm SD), or median (IQR).

Abbreviations: CVD: cardiovascular disease; BMI: body mass index; SBP: systolic blood pressure; Chol-HDL: cholesterol-HDL; DM: diabetes mellitus; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.

[#] Defined as the presence of albuminuria, neuropathy or DRP; * defined as non-smoking patients without a history of CVD and microvascular complications.

Table 2. Relative survival for men and women with T2D compared with men and women with the same age from the general population.

Men							Women					
Follow-up	N	Death	Lost to follow-up	COS	CES	Relative cumulative survival	N	Death	Lost to follow-up	COS	CES	Relative cumulative survival
0-1	800	36	1	0.96	0.97	0.99 (0.97 - 1.00)	1015	35	2	0.97	0.97	0.99 (0.98 - 1.00)
1-2	763	38	0	0.91	0.93	0.97 (0.95 - 0.99)	978	32	0	0.93	0.94	0.99 (0.97 - 1.00)
2-3	725	38	0	0.86	0.90	0.96 (0.93 - 0.98)	946	53	0	0.88	0.92	0.96 (0.94 - 0.98)
3-4	687	28	1	0.82	0.87	0.95 (0.92 - 0.98)	893	40	2	0.84	0.89	0.95 (0.92 - 0.97)
4-5	658	31	0	0.79	0.83	0.94 (0.91 - 0.98)	851	41	0	0.80	0.86	0.94 (0.91 - 0.96)
5-6	627	35	1	0.74	0.80	0.93 (0.89 - 0.96)	810	52	4	0.75	0.83	0.91 (0.88 - 0.94)
6-7	591	30	3	0.70	0.77	0.91 (0.87 - 0.95)	754	53	6	0.72	0.79	0.90 (0.87 - 0.94)
7-8	558	26	1	0.67	0.74	0.91 (0.86 - 0.95)	715	40	0	0.68	0.76	0.89 (0.85 - 0.92)
8-9	531	22	0	0.64	0.71	0.91 (0.86 - 0.95)	675	38	3	0.64	0.73	0.87 (0.83 - 0.91)
9-10	509	20	0	0.62	0.68	0.91 (0.86 - 0.96)	634	30	0	0.61	0.70	0.86 (0.82 - 0.91)
10-11	489	15	58	0.60	0.65	0.92 (0.86 - 0.97)	604	35	62	0.57	0.67	0.85 (0.80 - 0.89)
11-12	416	22	101	0.56	0.62	0.90 (0.85 - 0.96)	507	28	93	0.54	0.64	0.84 (0.79 - 0.88)
12-13	293	17	3	0.53	0.59	0.89 (0.83 - 0.95)	386	26	4	0.50	0.61	0.82 (0.77 - 0.88)
13-14	273	16	60	0.49	0.56	0.88 (0.81 - 0.94)	356	18	97	0.47	0.58	0.82 (0.76 - 0.87)

Abbreviations: N: number of patients at risk; COS: cumulative observed survival; CES: cumulative expected survival.

Table 3. Relative survival after 10 years for different subgroups.

Category	Men		Women		p-value [#]
	N	Relative survival (95% CI)	N	Relative survival (95% CI)	
Age < 60	276	0.98 (0.94 – 1.01)	224	0.93 (0.87 – 0.96)	0.052
Age ≥ 60 and < 75	337	0.89 (0.81 – 0.96)	448	0.89 (0.84 – 0.95)	0.870
Age ≥ 75	187	0.59 (0.42 – 0.80)	343	0.68 (0.56 – 0.79)	0.909
Diabetes duration <2 years	206	0.99 (0.92 – 1.06)	232	0.97 (0.90 – 1.03)	0.626
BMI < 25	174	0.79 (0.66 – 0.92)	169	0.80 (0.67 – 0.91)	0.914
BMI 25-30	392	0.94 (0.87 – 1.01)	377	0.87 (0.79 – 0.94)	0.126
BMI > 30	232	0.91 (0.83 – 0.99)	465	0.89 (0.83 – 0.94)	0.616
Non-smokers	583	0.93 (0.87 – 0.99)	869	0.86 (0.82 – 0.92)	0.121
Smokers	206	0.84 (0.75 – 0.92)	136	0.84 (0.73 – 0.92)	0.931
No history of CVD	492	0.99 (0.94 – 1.05)	717	0.92 (0.87 – 0.97)	0.046
History of CVD	306	0.73 (0.63 – 0.82)	298	0.70 (0.61 – 0.79)	0.648
Normoalbuminuria	450	1.00 (0.94 – 1.05)	655	0.95 (0.90 – 1.00)	0.214
Microalbuminuria	266	0.81 (0.71 – 0.90)	277	0.75 (0.66 – 0.84)	0.444
Macroalbuminuria	168	0.59 (0.40 – 0.78)	46	0.54 (0.34 – 0.73)	0.886
No microvascular complications	314	1.01 (0.95 – 1.07)	428	0.98 (0.93 – 1.03)	0.488
Microvascular complications*	464	0.82 (0.74 – 0.89)	546	0.77 (0.71 – 0.84)	0.395
Low risk profile [†]	154	1.08 (1.00 – 1.14)	270	1.01 (0.94 – 1.07)	0.106

Abbreviations: BMI: body mass index; CVD: cardiovascular disease.

Difference between men and women * Defined as the presence of albuminuria, neuropathy or DRP; † defined as non-smoking patients without a history of CVD and microvascular complications.




Fig. 1. Relative survival with 95% CI for men and women with T2D. Men: blue line, Women: red line.




Fig. 2. Relative survival with 95% CI for men and women with T2D after 10 years in different subgroups. Men: blue, women: red.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5,6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	6,7,8
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7,8

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	18 (Table 2)
		(b) Give reasons for non-participation at each stage	18 (Table 2)
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8 and 17 (Table 1)
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12,13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12,13
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Sex differences in survival of patients with type 2 diabetes in primary care (ZODIAC-50).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-015870.R1
Article Type:	Research
Date Submitted by the Author:	15-Jul-2017
Complete List of Authors:	Hendriks, Steven; Isala, Diabetes centre van hateren, Kornelis; Langerhans Medical Research Group Groenier, Klaas; University Medical Center Groningen, Department of General Practice Landman, Gijs; Langerhans Medical Research Group; Gelre hospital Maas, Angela; Radboud University Medical Center Bilo, Henk; Isala, Diabetes centre; University Medical Center Groningen Kleefstra, Nanne; Langerhans Medical Research Group; University Medical Center Groningen
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	type 2 diabetes, sex differences, relative survival

SCHOLARONE™
Manuscripts

1
2
3 Sex differences in survival of patients with type 2 diabetes in primary care (ZODIAC-50).
4
5
6

7 Short title: Sex differences in survival with type 2 diabetes
8
9

10
11 S.H. Hendriks MD¹, K.J.J. van Hateren MD PhD², K.H. Groenier PhD³, G.W.D. Landman
12
13 MD PhD^{2,4}, A.H.E.M. Maas MD PhD⁵, H.J.G. Bilo MD PhD FRCP^{1,6,7}, N. Kleefstra MD
14
15 PhD^{2,6}
16
17
18
19

20
21 ¹ Diabetes Centre, Isala, Zwolle, the Netherlands

22
23 ² Langerhans Medical Research Group, Zwolle, the Netherlands

24
25 ³ Department of General Practice, University of Groningen and University Medical Center
26
27 Groningen, Groningen, the Netherlands

28
29 ⁴ Department of Internal Medicine, Gelre hospital, Apeldoorn, the Netherlands

30
31 ⁵ Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands

32
33 ⁶ Department of Internal Medicine, University of Groningen and University Medical Center
34
35 Groningen, Groningen, the Netherlands;

36
37
38 ⁷ Department of Internal Medicine, Isala, Zwolle, the Netherlands
39
40
41

42 Corresponding author:

43
44 Steven H. Hendriks

45
46 Diabetes Centre, Isala

47
48 Dr. Spanjaardweg 11, 2nd floor, 8025 BT Zwolle; the Netherlands

49
50 T: +31-384247763; F: +31-384247695

51
52 E: stevenh_hendriks@hotmail.com
53
54
55
56
57
58
59
60

Abstract

Objective: To investigate sex differences in survival of primary care treated patients with type 2 diabetes in the Netherlands.

Setting: Primary care.

Participants: A total of 1815 patients who participated in a prospective observational cohort study (ZODIAC) was included of which 56% was female. Inclusion took place in 1998, 1999 and 2001. Vital status was assessed in 2013.

Main outcome measure: Relative survival of men and women with T2DM. The relative survival rate was expressed as the ratio of observed survival of patients divided by the survival of the general population in the Netherlands with comparable age.

Results: After 14 years, 888 (49%) patients had died. The relative survival rate was 0.88 (0.81 – 0.94) for men and 0.82 (0.76 – 0.87) for women with type 2 diabetes after 14 years (p-value for difference between sexes = 0.169). In patients without a history of cardiovascular diseases the relative survival was 0.99 (0.94 – 1.05) in men and 0.92 (0.87 – 0.97) in women (p-value for difference between sexes = 0.046).

Conclusions: The survival of men and women with type 2 diabetes was 12% and 18% lower, respectively, after 14 years of follow-up compared to men and women in the general population. This corresponds to a decrease in median survival of 2.2 and 3.5 years in men and women respectively. Only for T2D patients without a history of CVD a significantly lower relative survival in women compared to men with T2D was found.

Article summary: Strengths and limitations of this study

- This study provides insight in the current situation concerning the survival of men and women with type 2 diabetes who are treated in primary care in the Netherlands.
- This study used the technique of relative survival analysis, hereby a comparison between the survival of type 2 diabetes patients and the expected survival of whole general population could be made.
- The survival rates of men and women in the general population were derived from mortality rates of the entire nation.
- The generalizability is limited to primary care.
- No data were known concerning clinical variables in the general population and therefore the results of the subgroups should be interpreted with caution.

Introduction

Mortality rates in patients with type 2 diabetes (T2D) are higher compared to the general population, which is predominantly caused by a higher occurrence of cardiovascular diseases in patients with T2D (1–3). This excess mortality rate is described to be more pronounced in women compared to men with T2D (2–5). In a recent meta-analysis, the relative risk for mortality of incident coronary heart disease was 2.8 in women and 2.0 in men compared to men and women without diabetes, respectively (2).

Current knowledge on sex differences in mortality is mostly based on older cohort studies.

Whether these results are still reflecting current practice is less clear, as the care for patients with T2D has significantly improved over the last years (6). In the Netherlands, most patients with T2D receive protocol-based treatment exclusively in primary care. The mortality in this population is low, which is probably the result of a general improvement in quality of diabetes care over the last years (7). It is less well established whether sex differences in mortality also exist in well-controlled primary care patients. Only a few studies have been recently conducted in countries with a comparable care system to the Netherlands (8–10). A study from Norway also described a more pronounced excess mortality rate in women with T2D, however this study also included secondary care treated patients (10). A retrospective study from the U.K in primary care found only a slightly higher hazard ratio for all-cause mortality in women than in men with T2D, when compared with non-diabetics (8).

The aim of the present study was to investigate the survival of prospectively followed men and women with T2D, treated in primary care, compared to men and women in the general population.

Materials and Methods

Study population and design

1
2
3 The study population consisted of patients who were included in the Zwolle Outpatient
4 Diabetes Project Integrating Available Care (ZODIAC) study. This study was initiated in
5 1998, in the Zwolle region of the Netherlands. The design and details of this study have been
6 published previously (11). In this study, general practitioners were assisted by hospital-based
7 diabetes specialist nurses in their care of patients with T2D. In the first year, 1,143 patients
8 with T2D were included in this prospective cohort study. Another 127 and 545 patients with
9 T2D entered this study in 1999 and 2001 respectively, resulting in a combined cohort of 1,815
10 patients. All patients with T2D were selected from general practices in Zwolle region of the
11 Netherlands. Patients with a very short life expectancy or insufficient cognitive capabilities
12 were excluded from participation as the care for these patients has not been delegated to
13 diabetes specialist nurses. Whether the life expectancy was long enough to be included in the
14 ZODIAC study was based on the judgement of the general practitioners.

15
16 The survival of this cohort was compared with the expected survival of men and women with
17 the same age from the general population in the Netherlands. These expected survival rates
18 were derived from data provided by Statistics Netherlands. This organization provides
19 survival rates for men and women of every age in the Netherlands (12).

20
21 This study was approved by the local ethical committee of Isala, Zwolle, the Netherlands. All
22 patients gave written informed consent.

23 24 25 *Data collection and measurements*

26
27 Before participating in the ZODIAC study, T2D was already diagnosed in all individuals by
28 their general practitioners based on the guidelines of the Dutch College of General
29 Practitioners (2 times a fasting plasma glucose level ≥ 7 mmol/l or one time a non-fasting
30 plasma glucose level ≥ 11.1 mmol/l accompanied by symptoms of hyperglycemia) (13).

1
2
3 Information on cardiovascular diseases, smoking and medication use was collected during the
4
5 check-up of the patient by the general practitioner or practice nurse at baseline of the study.
6
7 Patients were considered to have a history of CVD if a history of angina pectoris, myocardial
8
9 infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting,
10
11 stroke or a transient ischemic attack was documented in the patient record of the general
12
13 practice. Data on heart failure was not collected as it was not properly documented at
14
15 baseline. Smoking was included in the analyses as a categorical variable (yes/no). Laboratory
16
17 and physical assessment data were collected at baseline during the annual check-up of the
18
19 patients by their general practitioner and practice nurse and included non-fasting lipid profile,
20
21 glycated hemoglobin (HbA1c), serum creatinine (SCr), urinary albumin-to-creatinine ratio
22
23 (ACR), blood pressure and information about neuropathy and diabetic retinopathy. ACR was
24
25 measured using immunonephelometry (Behring Nephelometer; Mannheim, Germany), and
26
27 blood pressure was measured twice with a Welch Allyn sphygmomanometer in the supine
28
29 position after at least 5 minutes of rest. Foot sensibility was tested with 5.07 Semmes-
30
31 Weinstein monofilaments. Neuropathy was defined as two or more errors in a test of three, at
32
33 least at one foot. Diabetic retinopathy (DRP) was investigated with a retinal camera and the
34
35 fundus photos were judged by an ophthalmologist. Microalbuminuria was defined as an
36
37 albumin-to-creatinine ratio between 3.5 and 35 mg/mmol for women and between 2.5 and 25
38
39 mg/mmol for men. Macroalbuminuria was defined as an albumin-to-creatinine ratio > 35
40
41 mg/mmol for women and > 25 mg/mmol for men. The same methods were used in each
42
43 baseline year to measure the laboratory and physical assessment data.
44
45
46
47
48
49
50

51 *Clinical endpoints*

52
53 The primary end-point was the relative survival rate of men and women with T2D compared
54
55 with the general population in the Netherlands. Secondary end-points were the relative
56
57
58
59
60

1
2
3 survival rates of patients with T2D in different subgroups, and the median survival of men
4
5 and women. Subgroups for the relative survival analyses were defined for: age (<60, 60-75
6
7 and >75 years), Body Mass Index (BMI) (<25, 25-30 and >30 kg/m²), smoking, history of
8
9 CVD, albuminuria (normo-, micro- and macroalbuminuria), microvascular complications
10
11 (defined as the presence of albuminuria, neuropathy or DRP) and for patients with a low CVD
12
13 risk (defined as non-smoking patients without a history of CVD and microvascular
14
15 complications). In 2013, vital status and cause of death of T2D patients were retrieved from
16
17 records maintained by the hospital and the general practitioners or from the nationwide
18
19 Municipal Personal Records Database. Causes of death were coded according to the
20
21 International Classification of Diseases, 9th revision (ICD-9). Cardiovascular death was
22
23 defined as death in which the principal cause of death was cardiovascular in nature, using
24
25 ICD-9 codes 390-459.
26
27
28
29
30
31

32 *Statistical analyses*

33
34 Statistical analyses were performed using SPSS version 20.0 for Windows (SPSS Inc.,
35
36 Chicago, Illinois, USA) and Stata 14 (StataCorp, College Station, Texas, USA). Baseline
37
38 results were expressed as mean with standard deviation (SD) or median with interquartile
39
40 range [IQR] for normally distributed and non-normally distributed data, respectively.
41
42 Differences were considered to be significant at a p-value of <0.05. Survival was calculated
43
44 using relative survival analysis (14). The relative survival rate was calculated by measuring
45
46 the ratio of survival of patients observed in our ZODIAC cohort in comparison to the survival
47
48 of men and women with corresponding age in the same baseline year in the general
49
50 population in the Netherlands. First, interval-specific and cumulative survival rates were
51
52 measured for both the study population and the general population, using the Hakulinen
53
54 method (15). The interval-specific observed survival rate for each follow-up year of the study
55
56
57
58
59
60

1
2
3 population was calculated based on the number of patients at risk, the number of deaths and
4
5 the number of patients lost to follow-up in each year. The interval-specific expected survival
6
7 rate for the general population was calculated using yearly-specific survival data of the
8
9 general population (12). Consequently, the cumulative survival rate was measured for both
10
11 the study group and the general population. Finally, the relative cumulative survival rate was
12
13 calculated. The relative cumulative survival rate for the total study population is described for
14
15 each of the 14 follow-up years for men and women separately. To investigate whether the
16
17 relative survival was significant different between sexes, the p-value was calculated at 14
18
19 years of follow-up. For the subgroup analyses, the relative cumulative survival rate is only
20
21 described after 10 years of follow-up. Cumulative survival rates after 10 years are described
22
23 due to the fact that 14 years survival data were only available for patients who were included
24
25 in 1998. The relative cumulative survival rates after 10 years are therefore more reliable. P-
26
27 values for the differences between sexes were calculated at 10 years of follow-up for the
28
29 subgroup analyses. An estimation of the median survival of the study population was
30
31 calculated using linear interpolation. For the general population, linear extrapolation with the
32
33 average difference between the cumulative survivals of the general population was conducted
34
35 first, before using linear interpolation to estimate the median survival (see supplementary file
36
37 1).

38 39 40 41 42 43 44 45 **Results**

46
47 Baseline results of the study population are described in Table 1. Fifty-six percent of the
48
49 patients were female. Mean age was 65.0 (11.8) years in men and 68.6 (11.6) years in women.
50
51 The median diabetes duration was 4.0 [1.8-9.0] and 5.0 [2.0-10.0] years in men and women,
52
53 respectively. Men smoked more frequently and had also more often albuminuria and a
54
55 previous history of CVD compared to women. Women had a higher systolic blood pressure, a
56
57
58
59
60

1
2
3 higher BMI, and more often diabetic retinopathy than men. Men were more often on diet
4
5 treatment only while women were more often on insulin. Lipid lowering drugs and
6
7 antiplatelet drugs were more often used in men.
8
9

10 11 *Relative survival analyses*

12
13 The incidence rate for all-cause mortality was 7.4 (6.7 – 8.2) and 7.2 (6.5 – 7.8) per 100
14
15 person years in men and women with T2D, respectively. The incidence rate for CVD
16
17 mortality was 3.1 (2.7 - 3.6) and 3.0 (2.6 - 3.4) per 100 person years in men and women with
18
19 T2D, respectively. The comparison between the survival of the patients with T2D and the
20
21 general population is presented in Table 2 and Fig. 1 for men and women separately. After 14
22
23 years, the relative survival rate was 0.88 (95%CI: 0.81 - 0.94) for men and 0.82 (95%CI: 0.76
24
25 – 0.87) for women with T2D (p-value for difference between sexes = 0.169). The estimated
26
27 median survival of men (mean age: 65.0) and women (mean age: 68.8) in the study population
28
29 was 13.8 and 13.0 years, respectively. In the general population, the estimated median
30
31 survival of men and women was 16.0 and 16.5 year respectively.
32
33
34
35
36
37

38 *Subgroup analyses*

39
40 The relative survival rate after 10 years for different subgroups is described in Table 3 and
41
42 Fig. 2 for men and women separately. In the subgroup of T2D patients without microvascular
43
44 complications, the relative survival rate of men and women with T2D was 1.01 (95%CI: 0.95
45
46 – 1.07) and 0.98 (95%CI: 0.93 – 1.03), respectively (p = 0.488). In patients with
47
48 microvascular complications, the relative survival rate decreased to 0.82 (95%CI: 0.74 – 0.89)
49
50 for men and 0.77 (95%CI: 0.71 – 0.84) for women with T2D (p = 0.395). In men and women
51
52 with low CVD risk (defined as non-smoking patients without a history of CVD and
53
54 microvascular complications) the relative survival rate was 1.08 (95%CI: 1.00 – 1.14) and
55
56
57
58
59
60

1
2
3 1.01 (0.94 – 1.07), respectively ($p = 0.106$). The relative survival rates of men <60 years, of
4
5 men with a BMI between 25 and 30 kg/m², of men without a history of CVD, and of men
6
7 without albuminuria were not significantly different from men in the general population. The
8
9 relative survival rate in women in all these categories was significantly lower compared to
10
11 women in the general population. For patients without a history of CVD, the relative survival
12
13 was significantly lower in women with T2D compared to men ($p = 0.046$).
14
15

16 17 **Discussion**

18
19 In primary care treated T2D patients, the relative survival of men and women was 12% and
20
21 18% lower after 14 years of follow-up compared to age-matched men and women in the
22
23 general population, respectively. This translates into an overall decrease in median survival of
24
25 2.2 years in men and 3.5 years in women with T2D compared to men and women in the
26
27 general population. Although the relative survival of women with T2D seems to be lower than
28
29 in male counterparts, no significant difference between sexes was found in the total study
30
31 population. The survival rate in certain subgroups of men with T2D (young age, no
32
33 albuminuria, no history of CVD, BMI 25-30) was comparable to the survival rate of men in
34
35 the general population. In women in these subgroups the relative survival was significantly
36
37 lower compared to women without T2D. Only for T2D patients without a history of CVD a
38
39 significantly lower relative survival in women compared to men with T2D was found.
40
41
42
43
44
45

46
47 The differences in relative survival between men and women in the total study population
48
49 could possibly be explained by both the higher age and longer diabetes duration in women
50
51 with T2D. Although women have a lower relative survival, it is not significantly lower
52
53 compared to men. When women would have the same age and the same diabetes duration as
54
55 men, the difference in relative survival would likely be smaller. This strengthens our
56
57 conclusion that in the total population there is no significant difference in relative survival
58
59
60

1
2
3 between sexes. Many studies have described a higher excess mortality rate in women than in
4
5 men with T2D (4,5,16). In our study, a higher impact of T2D in women was only found in
6
7 the subgroup of patients without a history of CVD. In subgroups of patients < 60 year of age,
8
9 without albuminuria and with a BMI between 25-30 kg/m² the relative survival of women
10
11 with T2D was lower compared to women in the general population but not lower compared to
12
13 the relative survival of men with T2D. The comparable survival of men with T2D without a
14
15 history of CVD to men in the general population has partly been described before by Kalyani
16
17 et al. (17). In a population without ischemic heart disease, they found an increased risk for the
18
19 combined outcome of ischemic heart disease and mortality in women with diabetes compared
20
21 to women without diabetes whereas they found no differences in men.
22
23
24
25
26

27 The decrease in median survival which is found in our study seems to be smaller than those
28
29 seen in previous studies. Results from the Framingham Heart Study showed that men and
30
31 women with diabetes lived on average 7.5 (95CI: 5.5 to 9.5) and 8.2 (95CI: 6.1 to 10.4) years
32
33 less compared to men and women without diabetes. However, this cohort started between
34
35 1948 and 1951 when treatment options for T2D were limited. In a more recent study from
36
37 Canada, for both men and women at the age of 55 on average a 5.0 (95CI: 4.9 to 5.1) and 6.0
38
39 (95CI: 5.9 to 6.1) years lower life expectancy was estimated compared to men and women
40
41 without diabetes (18). Although patient characteristics differ between studies and various
42
43 methods were used to measure survival, it may indicate that the loss of life years due to
44
45 diabetes is decreasing in both men and women.
46
47
48
49
50

51 Although different theories have been described which may explain the observed sex
52
53 difference in the impact of diabetes on survival, it is still not completely understood.
54
55

56 Undertreatment of women with T2D is mentioned as a possible explaining factor. A lower
57
58
59
60

1
2
3 prescription percentage for aspirin and lipid lowering drugs was found in women compared to
4
5 men with T2D (19). However, in a recent study in primary care we did not find significant sex
6
7 differences in these prescribed medications (20). The sex difference in survival may also be
8
9 explained by a greater excess in cardiovascular risk factors between women with and without
10
11 T2D compared to their male counterparts (4,21). This greater excess in risk factors is
12
13 probably the result of a more favorable risk factor profile and a lower insulin resistance in
14
15 women without diabetes compared to men (21,22). Although the relatively higher risk for
16
17 women with T2D for fatal ischemic heart disease remained significant in various meta-
18
19 analyses after adjustment for other cardiovascular risk factors, it may still be an explanation as
20
21 only traditional risk factors were taken into account (2,4). The lower relative survival could
22
23 also be a result of a higher prevalence of obesity in women with T2D. In the Netherlands, the
24
25 prevalence of obesity is described to be 25 to 50% higher in women compared to men with
26
27 T2D, whereas the prevalence of overweight is 20 to 35% higher in men compared to women
28
29 in different age categories (20). Knowing that overweight is associated with a lower mortality
30
31 risk and obesity with a higher mortality risk compared to patient with a normal weight, this
32
33 could possibly be one of the explaining factors for the higher relative mortality rate in women
34
35 with T2D (23). Finally, the relative higher mortality in women with T2D may be a result of
36
37 underdiagnosis of ischemic heart disease in women. Women with T2D have less obstructive
38
39 coronary disease compared to men, with higher rates of microvascular coronary dysfunction
40
41 that may be more difficult to diagnose and treat (24). Also, a higher prevalence of
42
43 undiagnosed heart failure with preserved ejection fraction (HFpEF) is described in women
44
45 compared to men with T2D (25). When focusing on the common symptoms and diagnostic
46
47 criteria for ischemic heart disease and HFpEF, these diagnoses could be easily missed in
48
49 women. This may lead to undertreatment of women, resulting in a higher mortality when
50
51 having T2D.
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Some limitations should be mentioned. First, according to Hakulinen, relative survival is the
6
7 ratio of the observed survival in a group of patients compared with the expected survival in a
8
9 group of individuals in the general population, who are comparable with the patients
10
11 concerning all possible factors affecting survival, except for the disease of interest (15). Our
12
13 choice to compare survival of patients with T2D from the Zwolle region with to the general
14
15 population can therefore be criticized. However, the underlying assumption by the use of the
16
17 expected survivals of the general population is that the deaths directly due to T2D are a
18
19 negligible proportion of all deaths in the general population. Second, although no specific
20
21 indications exist which suggests that people in the Zwolle region are healthier or unhealthier
22
23 compared to the whole population in the Netherlands, we do not now that for sure. It would
24
25 have been better if we had used a control population from the Zwolle region, but
26
27 unfortunately such a control population was not available. Third, no data were known
28
29 concerning clinical variables in the general population, as we did not used a specific control
30
31 group but expected survival rates which were derived from mortality rates of the entire nation.
32
33 Therefore the results of the subgroups should be interpreted with caution. Fourth, the number
34
35 of patients in subgroups was sometimes relatively low which has decreased the precision of
36
37 the estimates. Fifth, selection bias has occurred in this study. The study population consisted
38
39 only of patients with T2D who are treated in primary care. Patients in secondary care often
40
41 have worse manifestations of T2D and more often macrovascular disease and will probably
42
43 have a lower survival. Furthermore, patients with a very short life expectancy or insufficient
44
45 cognitive capabilities were also excluded from participation. Although these limitations imply
46
47 that the generalizability of our results is limited to primary care, it is still representative for a
48
49 large part of the T2D population due to the fact that the majority (>85%) of the patients with
50
51 T2D is treated in primary care in the Netherlands (26). In this group of patients with T2D, the
52
53
54
55
56
57
58
59
60

1
2
3 survival is only 2.2 years lower in men and 3.5 years lower in women compared to men and
4
5 women the general population. In patients with T2D with no microvascular complication and
6
7 in patients with a low risk profile, even no difference in survival compared to the general
8
9 population was found.
10

11
12
13
14 In conclusion, the relative survival in men and women with T2D compared to the general
15
16 population was 12% and 18% lower. The results of this study further show that survival in
17
18 subgroups of men (i.e. younger men, no albuminuria, no history CVD, BMI between 25 and
19
20 30) is comparable to men in the general population, while the survival in women in these
21
22 subgroups is still lower compared to women in the general population. Only in women with
23
24 T2D without a history of CVD the impact of diabetes on survival is higher compared to men
25
26 with T2D.
27
28
29
30

31
32 Author Contributions: SHH, KJJH, KHG, HJGB and NK designed the study. SHH, KJJH and
33
34 GWDL acquired the data. SHH, KJJH and KHG analysed the data. SHH, KJJH, KHG,
35
36 GWDL, AHEMM, HJGB and NK interpreted the data. SHH and KJJH drafted the
37
38 manuscript. KHG, GWDL, AHEMM, HJGB and NK reviewed and edited the manuscript. All
39
40 authors read and approved the final manuscript.
41

42
43 Funding statement: This research received no specific grant from any funding agency in the
44
45 public, commercial or not-for-profit sectors.
46

47
48 Competing interests: None declared.

49
50 Ethics approval: This study was approved by the local ethical committee of Isala, Zwolle, the
51
52 Netherlands. All patients gave written informed consent.

53
54 Data sharing statement: No additional data are available.
55
56
57
58
59
60

References

1. Barnett KN, Ogston SA, McMurdo MET, Morris AD, Evans JMM. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland. *Diabet Med J Br Diabet Assoc.* 2010 Oct;27(10):1124–9.
2. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia.* 2014 Aug;57(8):1542–51.
3. Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. *Diabetes Care.* 2013 Sep;36(9):2582–90.
4. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ.* 2006 Jan 14;332(7533):73–8.
5. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. *Diabetes Care.* 2000 Jul;23(7):962–8.
6. van Hateren KJJ, Drion I, Kleefstra N, Groenier KH, Houweling ST, van der Meer K, et al. A prospective observational study of quality of diabetes care in a shared care setting: trends and age differences (ZODIAC-19). *BMJ Open.* 2012;2(4).
7. Lutgers HL, Gerrits EG, Sluiter WJ, Ubink-Veltmaat LJ, Landman GWD, Links TP, et al. Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10). *PloS One.* 2009;4(8):e6817.
8. Liang H, Vallarino C, Joseph G, Manne S, Perez A, Zhang S. Increased risk of subsequent myocardial infarction in patients with type 2 diabetes: a retrospective cohort study using the U.K. General Practice Research Database. *Diabetes Care.* 2014;37(5):1329–37.
9. Hyvärinen M, Tuomilehto J, Laatikainen T, Söderberg S, Eliasson M, Nilsson P, et al. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. *Cardiovasc Diabetol.* 2009;8:17.
10. Madssen E, Vatten L, Nilsen TI, Midthjell K, Wiseth R, Dale AC. Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study. *Scand Cardiovasc J SCJ.* 2012 Aug;46(4):219–25.
11. Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Rischen RO, Meyboom-de Jong B. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. *Neth J Med.* 2005 Mar;63(3):103–10.
12. Data published by Statistics Netherlands. In Dutch: “Centraal Bureau voor de Statistiek”. [Internet]. Available from: <http://statline.cbs.nl/Statweb/selection/?DM=SLNL&PA=70701NED&VW=T>

13. Rutten GEHM, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K, et al. NHG-Standaard Diabetes Mellitus Type 2. Eerste herziening. Huisarts Wet. 1999;42(2):67–84.
14. Hockey R, Tooth L, Dobson A. Relative survival: a useful tool to assess generalisability in longitudinal studies of health in older persons. *Emerg Themes Epidemiol*. 2011;8(1):3.
15. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. *Biometrics*. 1982 Dec;38(4):933–42.
16. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. *Arch Intern Med*. 2002 Aug 12;162(15):1737–45.
17. Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. *Diabetes Care*. 2014;37(3):830–8.
18. Loukine L, Waters C, Choi BC, Ellison J. Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. *Popul Health Metr*. 2012;10(1):7.
19. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. *Diabetes Care*. 2005 Mar;28(3):514–20.
20. Hendriks SH, van Hateren KJJ, Groenier KH, Houweling ST, Maas AHEM, Kleefstra N, et al. Sex Differences in the Quality of Diabetes Care in the Netherlands (ZODIAC-45). *PloS One*. 2015;10(12):e0145907.
21. Wannamethee SG, Papacosta O, Lawlor DA, Whincup PH, Lowe GD, Ebrahim S, et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. *Diabetologia*. 2012 Jan;55(1):80–7.
22. Orchard TJ, Becker DJ, Kuller LH, Wagener DK, LaPorte RE, Drash AL. Age and sex variations in glucose tolerance and insulin responses: parallels with cardiovascular risk. *J Chronic Dis*. 1982 Feb;35(2):123–32.
23. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013 Jan 2;309(1):71–82.
24. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, et al. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Coll Cardiol*. 2013 Apr 30;61(17):1767–76.

- 1
2
3 25. Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten
4 GEHM, et al. High prevalence of previously unknown heart failure and left ventricular
5 dysfunction in patients with type 2 diabetes. *Diabetologia*. 2012 Aug;55(8):2154–62.
6
7 26. InEen. In Dutch: Transparante ketenzorg diabetes mellitus, COPD en VRM rapportage
8 zorggroepen over 2013. 2014 Jun.
9

10
11
12 **Supplementary files**

13
14 Supplementary file 1: estimation of the median survival
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Tables and figures**
4
5
6

7 **Table 1. Baseline characteristics of the study population.**

	Total (n = 1815)	Men (n = 800)	Women (n = 1015)	p-value
Age (years)	67.0 (\pm 11.8)	65.0 (\pm 11.8)	68.6 (\pm 11.6)	<0.001
Diabetes duration (years)	4.0 (2.0-9.0)	4.0 (1.8-9.0)	5.0 (2.0-10.0)	0.017
History of CVD	605 (33.3)	307 (38.4)	298 (29.4)	<0.001
Smoking	342 (19.0)	206 (26.0)	136 (13.5)	<0.001
BMI (kg/m ²)	29.1 (\pm 4.8)	28.2 (\pm 4.1)	29.9 (\pm 5.2)	<0.001
SBP (mmHg)	151.5 (\pm 24.4)	147.2 (\pm 23.4)	155.0 (\pm 24.5)	<0.001
HbA1c (mmol/mol)	7.0 (6.3-8.1)	6.9 (6.2-8.1)	7.1 (6.4-8.1)	0.131
Creatinine (μ mol/L)	92.0 (82.0-104.0)	98.0 (89.0-109.0)	86.0 (77.0-97.0)	<0.001
Chol-HDL ratio	4.8 (3.9-5.9)	4.9 (4.0-6.0)	4.7 (3.8-5.8)	0.001
Retinopathy	190 (10.9)	70 (9.1)	120 (12.3)	0.030
Microalbuminuria	544 (30.8)	267 (34.0)	277 (28.3)	0.011
Macroalbuminuria	114 (6.5)	68 (8.7)	46 (4.7)	0.001
Neuropathy	477 (26.6)	212 (26.7)	265 (26.6)	0.931
Microvascular complications [#]	1012 (57.7)	466 (59.7)	546 (56.1)	0.120
Low CVD risk*	424 (23.4)	154 (19.3)	270 (26.6)	<0.001
DM treatment				
Diet	318 (17.5)	158 (19.8)	160 (15.8)	0.026
Oral only	1230 (67.8)	540 (67.6)	690 (68.0)	0.834
Insulin	262 (14.5)	99 (12.4)	163 (16.1)	0.028
ACEi/ARB	433 (27.1)	179 (25.1)	254 (28.7)	0.108
Lipid lowering drugs	278 (15.6)	139 (17.7)	139 (13.9)	0.030
Antiplatelet drugs	279 (15.6)	139 (17.6)	140 (14.0)	0.035
Death	888 (48.9)	381 (47.6)	507 (50.0)	0.325
CVD death	374 (20.6)	161 (20.1)	213 (21.0)	0.653

28 Values are depicted as n (%), mean (\pm SD), or median (IQR).

29 Abbreviations: CVD: cardiovascular disease; BMI: body mass index; SBP: systolic blood pressure;
30 Chol-HDL: cholesterol-HDL; DM: diabetes mellitus; ACEi: angiotensin-converting enzyme inhibitor;
31 ARB: angiotensin receptor blocker.

32 [#] Defined as the presence of albuminuria, neuropathy or DRP; * defined as non-smoking patients
33 without a history of CVD and microvascular complications.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Relative survival for men and women with T2D compared with men and women with the same age from the general population.

Men							Women					
Follow-up	N	Death	Lost to follow-up	COS	CES	Relative cumulative survival	N	Death	Lost to follow-up	COS	CES	Relative cumulative survival
0-1	800	36	1	0.96	0.97	0.99 (0.97 - 1.00)	1015	35	2	0.97	0.97	0.99 (0.98 – 1.00)
1-2	763	38	0	0.91	0.93	0.97 (0.95 - 0.99)	978	32	0	0.93	0.94	0.99 (0.97 – 1.00)
2-3	725	38	0	0.86	0.90	0.96 (0.93 – 0.98)	946	53	0	0.88	0.92	0.96 (0.94 – 0.98)
3-4	687	28	1	0.82	0.87	0.95 (0.92 – 0.98)	893	40	2	0.84	0.89	0.95 (0.92 – 0.97)
4-5	658	31	0	0.79	0.83	0.94 (0.91 – 0.98)	851	41	0	0.80	0.86	0.94 (0.91 – 0.96)
5-6	627	35	1	0.74	0.80	0.93 (0.89 – 0.96)	810	52	4	0.75	0.83	0.91 (0.88 – 0.94)
6-7	591	30	3	0.70	0.77	0.91 (0.87 – 0.95)	754	33	6	0.72	0.79	0.90 (0.87 – 0.94)
7-8	558	26	1	0.67	0.74	0.91 (0.86 – 0.95)	715	40	0	0.68	0.76	0.89 (0.85 – 0.92)
8-9	531	22	0	0.64	0.71	0.91 (0.86 – 0.95)	675	38	3	0.64	0.73	0.87 (0.83 – 0.91)
9-10	509	20	0	0.62	0.68	0.91 (0.86 – 0.96)	634	30	0	0.61	0.70	0.86 (0.82 – 0.91)
10-11	489	15	58	0.60	0.65	0.92 (0.86 – 0.97)	604	35	62	0.57	0.67	0.85 (0.80 – 0.89)
11-12	416	22	101	0.56	0.62	0.90 (0.85 – 0.96)	507	28	93	0.54	0.64	0.84 (0.79 – 0.88)
12-13	293	17	3	0.53	0.59	0.89 (0.83 – 0.95)	386	26	4	0.50	0.61	0.82 (0.77 – 0.88)
13-14	273	16	60	0.49	0.56	0.88 (0.81 – 0.94)	356	18	97	0.47	0.58	0.82 (0.76 – 0.87)

Abbreviations: N: number of patients at risk; COS: cumulative observed survival; CES: cumulative expected survival.

Table 3. Relative survival after 10 years for different subgroups.

Category	Men				Women				p-value [#]
	N	Death	Lost to follow-up	Relative survival (95% CI)	N	Death	Lost to follow-up	Relative survival (95% CI)	
Age < 60	276	24	3	0.98 (0.94 – 1.01)	224	26	4	0.93 (0.87 – 0.96)	0.052
Age ≥ 60 and < 75	337	126	3	0.89 (0.81 – 0.96)	448	123	5	0.89 (0.84 – 0.95)	0.870
Age ≥ 75	187	154	1	0.59 (0.42 – 0.80)	343	245	8	0.68 (0.56 – 0.79)	0.909
Diabetes duration <2 years	206	76	1	0.99 (0.92 – 1.06)	232	83	5	0.97 (0.90 – 1.03)	0.626
BMI < 25	174	96	1	0.79 (0.66 – 0.92)	169	83	4	0.80 (0.67 – 0.91)	0.914
BMI 25-30	392	135	4	0.94 (0.87 – 1.01)	377	153	6	0.87 (0.79 – 0.94)	0.126
BMI > 30	232	73	2	0.91 (0.83 – 0.99)	465	154	7	0.89 (0.83 – 0.94)	0.616
Non-smokers	583	226	5	0.93 (0.87 – 0.99)	869	349	14	0.86 (0.82 – 0.92)	0.121
Smokers	206	76	2	0.84 (0.75 – 0.92)	136	40	3	0.84 (0.73 – 0.92)	0.931
No history of CVD	492	132	3	0.99 (0.94 – 1.05)	717	228	11	0.92 (0.87 – 0.97)	0.046
History of CVD	306	172	4	0.73 (0.63 – 0.82)	298	166	6	0.70 (0.61 – 0.79)	0.648
Normoalbuminuria	450	116	3	1.00 (0.94 – 1.05)	655	198	11	0.95 (0.90 – 1.00)	0.214
Microalbuminuria	266	134	3	0.81 (0.71 – 0.90)	277	138	5	0.75 (0.66 – 0.84)	0.444
Macroalbuminuria	68	45	1	0.59 (0.40 – 0.78)	46	28	1	0.54 (0.34 – 0.73)	0.886
No microvascular complications	314	70	1	1.01 (0.95 – 1.07)	428	104	5	0.98 (0.93 – 1.03)	0.488
Microvascular complications*	464	227	5	0.82 (0.74 – 0.89)	546	263	10	0.77 (0.71 – 0.84)	0.395
Low risk profile [†]	154	21	1	1.08 (1.00 – 1.14)	270	58	4	1.01 (0.94 – 1.07)	0.106

Abbreviations: BMI: body mass index; CVD: cardiovascular disease. # Difference between men and women * Defined as the presence of albuminuria, neuropathy or DRP; † defined as non-smoking patients without a history of CVD and microvascular complications.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1. Relative survival with 95% CI for men and women with T2D. Men: blue line, Women: red line.




Fig. 2. Relative survival with 95% CI for men and women with T2D after 10 years in different subgroups. Men: blue, women: red.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1. Relative survival with 95% CI for men and women with T2D. Men: blue line, Women: red line.

180x110mm (300 x 300 DPI)

review only




Fig. 2. Relative survival with 95% CI for men and women with T2D after 10 years in different subgroups. Men: blue, women: red.

109x176mm (300 x 300 DPI)

Supplementary file 1 Estimation of the median survival

We used the following formula to estimate the median survival:

$$X2 \text{ (median survival)} = ((Y2 - Y1) (X3 - X1) / (Y3 - Y1)) + x1$$

Whereby (using men as an example):

X1 = the follow-up year in which more than 50% was still alive at the end (for men in our cohort, the 13th follow-up year)

X3 = the follow-up year in which less than 50% was still alive at the end (for men in our cohort, the 14th follow-up year)

Y1 = the cumulative survival at the end of X1 (for men cumulative survival 13th follow-p year = 0.5294 (rounded of 0.53))

Y2 = the median (= cumulative survival of 0.5)

Y3 = the cumulative survival at the end of X3 (for men cumulative survival 14th follow-p year = 0.4945)

$$\text{Median survival of men with T2D} = ((0.5 - 0.5294) (14 - 13) / (0.4945 - 0.5294)) + 13 = 13.8424 \text{ (rounded of 13.8).}$$

For the general population, linear extrapolation with the average difference between the cumulative survivals of the general population was conducted first, before using linear interpolation to estimate the median survival. We had to do that because after 14 years of follow-up, still more than 50% of the general population was alive (for men after 14 years the cumulative expected survival was 0.56).

For identifying X1, X3, Y1 and Y3 of the general population we used the following steps:

1. We calculated the average difference between the cumulative survivals of the 14 follow-up years (for men in our study population 0.031054)
2. We extrapolated the cumulative survival by extracting this average difference from the cumulative survival of the previous year (see table 1).
3. Finally we measured the median follow-up by using the estimated cumulative survival of the 16th and 17th follow-up year.

Table 1. Extrapolation for men in the general population.

Follow-up year	Cumulative survival	Comment
12 – 13	0.5922	Calculated
13 - 14	0.5628	Calculated
14 - 15	$(0.5628 - 0.031054) = 0.531746$	Estimated with extrapolation
15 – 16	$(0.531746 - 0.031054) = 0.500692$	Estimated with extrapolation
16 – 17	$(0.500692 - 0.031054) = 0.469638$	Estimated with extrapolation

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5,6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	6,7,8
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7,8

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	18 (Table 2)
		(b) Give reasons for non-participation at each stage	18 (Table 2)
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8 and 17 (Table 1)
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12,13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10,11,12,13
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.